Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069164 | 1.00 | MAPT (0.45) | MAPTTSHRALDH1A1KMT2ACYP1A2 | |
| SCHEMBL582142 | 1.00 | MAPT (0.45) | MAPTTSHRALDH1A1KMT2ACYP1A2 | |
| SCHEMBL3075705 | 0.90 | PPARG (0.40) | MAPTTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL582086 | 0.90 | PPARG (0.40) | MAPTTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL3075222 | 0.90 | PPARG (0.40) | MAPTTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL581342 | 0.90 | NPSR1 (0.43) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL3072810 | 0.90 | NPSR1 (0.43) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL3073450 | 0.90 | NPSR1 (0.43) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL582515 | 0.88 | MEN1 (0.42) | MAPTALDH1A1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL3073122 | 0.88 | MEN1 (0.42) | MAPTALDH1A1KMT2ACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | MAPT 4513/4885TSHR 92/4885ALDH1A1 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.